Fresenius group in figures

€ in millions 2010 2009 2008 2007 2006
1 2008 before special items from the APP acquisition;
2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.

2 Net income attributable to Fresenius SE & Co. KGaA
3 Equity including noncontrolling interest
4 Investments in property, plant and equipment and intangible assets, acquisitions
5 2006 pro forma Renal Care Group, excluding earnings from the divestiture of US dialysis clinics as well as their first quarter 2006 earnings
6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics
7 Proposal
8 Adjusted for share split in February 2007
9 2008 pro forma APP Pharmaceuticals and excluding special items from the APP-acquisition
10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR
Sales and Earnings          
Sales 15,972 14,164 12,336 11,358 10,777
EBIT 2,418 2,054 1,7271 1,609 1,444
Net income2 6601 5141 4501 410 330
Depreciation and amortization 639 562 783 421 399
Earnings per ordinary share in € 4.081 3.181 2.851 2.64 2.158
Earnings per preference share in € 4.081 3.191 2.861 2.65 2.168
Cash flow and Balance sheet          
Operating cash flow 1,911 1,553 1,074 1,296 1,052
Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%
Total assets 23,577 20,882 20,544 15,324 15,024
Non-current assets 17,142 15,519 15,466 11,033 10,918
Equity3 8,844 7,491 6,943 6,059 5,728
Net debt 8,015 7,879 8,417 5,338 5,611
Net debt/EBITDA5, 9 2.6 3.0 3.6 2.6 3.0
Equity ratio3 38% 36% 34% 40% 38%
Investments4 1,402 931 4,617 1,318 4,314
Profitability          
EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%
Return on equity after taxes (ROE)4, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%
Return on operating assets (ROOA)5, 9 11.6% 10.5% 9.8% 11.4% 10.4%
Return on invested capital (ROIC)5, 9 8.9% 8.2% 7.3% 8.4% 7.4%
Dividend per ordinary share in € 0.867 0.75 0.70 0.66 0.57
Employees (December 31) 137,552 130,510 122,217 114,181 104,872

€ in millions 2010 2009 2008 2007 2006
1 2008 before special items from the APP acquisition;
2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.

2 Net income attributable to Fresenius SE & Co. KGaA
3 Equity including noncontrolling interest
4 Investments in property, plant and equipment and intangible assets, acquisitions
5 2006 pro forma Renal Care Group, excluding earnings from the divestiture of US dialysis clinics as well as their first quarter 2006 earnings
6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics
7 Proposal
8 Adjusted for share split in February 2007
9 2008 pro forma APP Pharmaceuticals and excluding special items from the APP-acquisition
10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR
Sales and Earnings          
Sales 15,972 14,164 12,336 11,358 10,777
EBIT 2,418 2,054 1,7271 1,609 1,444
Net income2 6601 5141 4501 410 330
Depreciation and amortization 639 562 783 421 399
Earnings per ordinary share in € 4.081 3.181 2.851 2.64 2.158
Earnings per preference share in € 4.081 3.191 2.861 2.65 2.168
Cash flow and Balance sheet          
Operating cash flow 1,911 1,553 1,074 1,296 1,052
Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%
Total assets 23,577 20,882 20,544 15,324 15,024
Non-current assets 17,142 15,519 15,466 11,033 10,918
Equity3 8,844 7,491 6,943 6,059 5,728
Net debt 8,015 7,879 8,417 5,338 5,611
Net debt/EBITDA5, 9 2.6 3.0 3.6 2.6 3.0
Equity ratio3 38% 36% 34% 40% 38%
Investments4 1,402 931 4,617 1,318 4,314
Profitability          
EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%
Return on equity after taxes (ROE)4, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%
Return on operating assets (ROOA)5, 9 11.6% 10.5% 9.8% 11.4% 10.4%
Return on invested capital (ROIC)5, 9 8.9% 8.2% 7.3% 8.4% 7.4%
Dividend per ordinary share in € 0.867 0.75 0.70 0.66 0.57
Employees (December 31) 137,552 130,510 122,217 114,181 104,872

Continue reading:
Summary of the fiscal year

QUICKFINDER

History

Tools